{"contentid": 487975, "importid": NaN, "name": "Exelixis enters licensing deal with Wuxi Biologics", "introduction": "Genomics-based drug discovery company Exelixis has announced an exclusive license agreement with WuXi Bio to support the continued expansion of its oncology biologics pipeline.", "content": "<p>Genomics-based drug discovery company Exelixis (Nasdaq: EXEL) has announced an exclusive license agreement with WuXi Bio (HKG: 2269) to support the continued expansion of its oncology biologics pipeline.</p>\n<p>The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind Cabometyx (cabozantinib), the Californian company&rsquo;s flagship product and global oncology franchise, which received its fourth approval from the US Food and Drug Administration in January.</p>\n<p><span class=\"pullQuote\">\"We are transforming how biologics are developed\"</span>Under the terms of the agreement, Exelixis will make an undisclosed and apparently &lsquo;modest&rsquo; upfront payment to WuXi Bio in exchange for an exclusive license to a panel of monoclonal antibodies to a pre-clinically validated target, discovered based on the Chinese firm&rsquo;s integrated technology platforms, for the development of antibody-drug conjugate, bispecific, and certain other novel tumor-targeting biologics applications.</p>\n<p>WuXi Bio will be eligible for development and commercialization milestones, as well as tiered royalties on net sales of any potential products commercialized from the panel.</p>\n<p>Peter Lamb, executive vice president, scientific strategy and chief scientific officer of Exelixis, said: &ldquo;Exelixis is pursuing a broad range of targets and therapeutic modalities to maximize the potential of our biologics pipeline to help patients with cancer.</p>\n<p>&ldquo;Our agreement with WuXi Bio enhances our growing biotherapeutics portfolio by providing an approach to a pre-clinically validated target that has already shown early clinical potential in cancer. We&rsquo;re looking forward to building on WuXi Bio&rsquo;s significant technical foundation and applying our own expertise as we bring this promising program into the Exelixis discovery organization.&rdquo;</p>\n<p>Chris Chen, chief executive of WuXi Biologics, said: &ldquo;We&rsquo;re glad to support Exelixis&rsquo; growing biotherapeutics pipeline with antibodies discovered through our integrated biologics technology platforms.</p>\n<p>&ldquo;WuXi Biologics will continue to develop globally leading next-generation technologies to accelerate and transform biologics discovery, development and manufacturing. With globally recognized technical capabilities and unparalleled capacities, we are transforming how biologics are developed in the global setting.&rdquo;&nbsp;</p>", "date": "2021-03-08 15:04:00", "meta_title": NaN, "meta_keywords": "biologics, Exelixis, WuXi, agreement, pipeline, discovery, oncology, company, exclusive, license, drug, support, enters, Wuxi, deal, licensing, continued", "meta_description": "Genomics-based drug discovery company Exelixis has announced an exclusive license agreement with WuXi Bio to support the continued expansion of its oncology bio", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-08 14:50:39", "updated": "2021-03-08 15:29:10", "access": NaN, "url": "https://www.thepharmaletter.com/article/exelixis-enters-licensing-deal-with-wuxi-biologics", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "exelixis-big-1.png", "image2id": "exelixis-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Asia Pacific, Deals, Focus On, Licensing", "geography_tag": "China, USA", "company_tag": "Exelixis, WuXi Biologics", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-08 15:04:00"}